Latest Insider Transactions at Evoke Pharma Inc (EVOK)
This section provides a real-time view of insider transactions for Evoke Pharma Inc (EVOK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Evoke Pharma Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Evoke Pharma Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2025
|
Nantahala Capital Management, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
148,153
-100.0%
|
$1,629,683
$11.0 P/Share
|
|
Dec 16
2025
|
Matthew J D'Onofrio Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,509
-100.0%
|
-
|
|
Dec 16
2025
|
Todd C Brady |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
27
-100.0%
|
-
|
|
Dec 16
2025
|
Mark Kowieski Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,815
-100.0%
|
-
|
|
Dec 16
2025
|
Malcolm R Hill |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
133
-100.0%
|
-
|
|
Dec 16
2025
|
Cam L Garner |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,330
-100.0%
|
-
|
|
Dec 16
2025
|
Marilyn R. Carlson Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
360
-100.0%
|
-
|
|
Nov 06
2025
|
Roger M. Klein > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,000
-8.9%
|
$90,000
$10.66 P/Share
|
|
Mar 21
2025
|
Matthew J D'Onofrio Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+9.24%
|
$2,000
$2.8 P/Share
|
|
Mar 20
2025
|
Mark Kowieski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+47.79%
|
$13,500
$3.21 P/Share
|
|
Feb 28
2025
|
Matthew J D'Onofrio Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,849
+43.71%
|
$20,547
$3.65 P/Share
|
|
Jan 28
2025
|
Nantahala Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
41
-0.03%
|
$164
$4.39 P/Share
|
|
Dec 14
2020
|
David A Gonyer CEO |
SELL
Open market or private sale
|
Direct |
23,954
-6.59%
|
$47,908
$2.94 P/Share
|
|
Dec 11
2020
|
David A Gonyer CEO |
SELL
Open market or private sale
|
Direct |
48,046
-11.67%
|
$96,092
$2.9 P/Share
|
|
Dec 11
2020
|
Matthew J D'Onofrio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,357
-12.44%
|
$80,714
$2.91 P/Share
|
|
Dec 10
2020
|
Matthew J D'Onofrio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,643
-1.71%
|
$11,286
$2.95 P/Share
|
|
Dec 09
2020
|
Matthew J D'Onofrio Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,000
+12.23%
|
$0
$0.4 P/Share
|
|
Dec 09
2020
|
David A Gonyer CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+14.88%
|
$0
$0.4 P/Share
|